TTTS, or twin-to-twin transfusion syndrome, is a serious pregnancy complication where identical twins sharing a single placenta receive unequal blood flow. One twin (the “donor”) transfers too much blood to the other (the “recipient”), creating dangerous imbalances for both. It affects roughly 10 to 15 percent of monochorionic diamniotic twin pregnancies, the type where twins share a placenta but have separate amniotic sacs.
How TTTS Develops
In any pregnancy with identical twins sharing a placenta, small blood vessel connections form naturally on the placental surface. In uncomplicated pregnancies, these connections balance out: blood flows back and forth between the twins more or less equally. In TTTS, the connections create a net one-way flow, sending blood consistently from one twin to the other.
The donor twin loses blood volume and produces less urine, which means less amniotic fluid in their sac. The recipient twin gets overloaded with blood, their heart works harder to handle the extra volume, and they produce excess amniotic fluid. This imbalance in oxygen and nutrient delivery develops gradually, which is why regular ultrasound monitoring of these pregnancies is critical.
How It’s Diagnosed
TTTS is diagnosed by ultrasound based on a striking difference in amniotic fluid levels between the two sacs. The recipient twin’s sac must have a deepest fluid pocket of 8 cm or more, while the donor twin’s sac measures 2 cm or less. The diagnosis also requires confirming a single shared placenta and that both twins are the same sex, which helps confirm they’re identical.
TTTS is different from a related condition called twin anemia-polycythemia sequence (TAPS), where the twins develop large differences in blood cell concentration without the dramatic fluid imbalance. In TAPS, you won’t see the telltale too-much-fluid, too-little-fluid pattern that defines TTTS.
The Five Stages
Doctors classify TTTS severity using a five-stage system developed by Dr. Rubén Quintero. These stages guide treatment decisions:
- Stage I: The fluid imbalance is present, but the donor twin’s bladder is still visible on ultrasound, meaning they’re still producing some urine.
- Stage II: The donor twin’s bladder can no longer be seen, indicating their kidneys are barely producing urine due to low blood volume.
- Stage III: Blood flow patterns become critically abnormal in one or both twins. This can include reversed blood flow in the umbilical cord or abnormal flow patterns in key veins, signaling the hearts are under serious strain.
- Stage IV: One or both twins develop hydrops, a dangerous buildup of fluid in body tissues and cavities that reflects heart failure.
- Stage V: One or both twins have died.
The condition doesn’t always progress neatly through each stage, which is why frequent monitoring matters even at earlier stages.
What TTTS Does to the Heart
The recipient twin bears the brunt of cardiac stress. Flooded with extra blood volume, their heart has to pump against increased resistance. Over time this causes the heart muscle to thicken, the heart chambers to enlarge, and the heart valves to start leaking. Regurgitation (backward leaking) across the tricuspid, mitral, pulmonary, and aortic valves has all been documented in recipient twins. These changes essentially look like a developing form of heart failure in the womb.
The donor twin faces different problems. With too little blood, their organs don’t get enough oxygen and nutrients, and their kidneys start shutting down, which is why amniotic fluid disappears from their sac.
Treatment Options
The primary treatment for TTTS diagnosed before 26 weeks is fetoscopic laser surgery. A thin scope is inserted through the mother’s abdomen into the uterus, and the surgeon uses laser energy to seal off the abnormal blood vessel connections on the placental surface. Each vessel is coagulated in short bursts until it turns white, confirming the connection is closed. The goal is to essentially divide the shared placenta into two separate territories, one for each twin.
A refinement called the Solomon technique improves on this by drawing a laser line across the entire placental surface connecting all the sealed spots. This catches tiny vessels the surgeon may not have been able to see individually, reducing the chance of recurrence or TAPS developing afterward.
An older approach, serial amnioreduction, involves repeatedly draining excess amniotic fluid from the recipient’s sac. This can relieve pressure and delay preterm labor but doesn’t address the underlying cause. A landmark trial published in the New England Journal of Medicine ended early because laser surgery showed clear superiority: at least one twin survived to 28 days in 76 percent of laser cases compared to 56 percent with amnioreduction. Babies treated with laser also had significantly fewer neurological complications at six months, with 52 percent free of issues compared to 31 percent after amnioreduction. Laser surgery is now the standard first-line treatment at specialized fetal surgery centers.
Survival Rates After Laser Surgery
Outcomes depend heavily on the stage at diagnosis. A 2024 meta-analysis found that both twins survived in about 73 percent of stage I cases, 68 percent at stage II, 48 percent at stage III, and 53 percent at stage IV. The chances of at least one twin surviving were higher across all stages: roughly 89 percent for stage I, 87 percent for stage II, 77 percent for stage III, and 80 percent for stage IV.
These numbers represent a major improvement over the pre-laser era, when untreated severe TTTS had mortality rates approaching 80 to 100 percent for both twins.
Long-Term Outlook for Survivors
Before laser therapy became widespread, at least one in five TTTS survivors had serious neurodevelopmental problems, most commonly cerebral palsy. Rates of neurological disability in that era ranged from 17 to 42 percent.
Laser surgery has substantially improved these numbers. Across studies from 1999 to 2016, cerebral palsy rates after laser treatment ranged from 3 to 12 percent, and broader neurodevelopmental impairment (including severe cognitive or motor delays, blindness, or deafness) was found in 4 to 18 percent of survivors. Some studies have reported higher rates of strabismus (crossed eyes) and, less commonly, microcephaly among TTTS survivors. Long-term follow-up data remain limited, but the trajectory since laser adoption has been consistently better than what came before.
Surviving twins are typically monitored with regular developmental assessments through early childhood. Heart function in former recipient twins also warrants follow-up, since the cardiac changes that develop in the womb can sometimes persist after birth, though many resolve on their own once normal circulation is established.